Six patients with de novo acute myeloid leukemia (AML) and a t(2;3)(p15-21;q26-27) were identified among approximately 1000 cases enrolled in the GIMEMA trial. The t(2;3) was the sole anomaly in three patients, whereas in three cases monosomy 7, trisomy 15 and 22, and trisomy 14 represented additional aberrations. No cryptic chromosome deletions at 5q, 7q, 12p, and 20q were observed. One patient carried a FLT3 D835 mutation; FLT3 internal tandem duplication (ITD) was not detected in three patients tested. Characterization of the translocation breakpoints using a 3q26 BAC contig specific for the PRDM3 locus showed that the breakpoints were located 5 0 to EVI1 as follows: within myelodysplatic syndrome (MDS) intron 1 (# 3), between MDS1 exons 2 and 3 in three patients (# 1, 2, 4) with a 170 bp cryptic deletion distal to the breakpoint in one (# 2), and in a more centromeric position spanning from intron 2 to the 5 0 region of EVI1 (# 6, 5). A set of 2p16-21 BAC probes showed that the breakpoints on chromosome 2p were located within BCL11A in two separate regions (# 1, 4 and # 2-5), within the thyroid adenoma-associated (THADA) gene (# 6) or distal to the ZFP36L2 locus (# 3). Regulatory elements were present in proximity of these breakpoints. RACE PCR studies revealed a chimeric transcript in 1/6 patient analyzed, but no fusion protein. Quantitative PCR showed a 21-58-fold overexpression of the EVI1 gene in all cases analyzed. The patients showed dysplasia of at least two myeloid cell lineages in all cases; they had a low-to-normal platelet count and displayed an immature CD34 þ CD117 þ immunophenotype. Despite intensive chemotherapy and a median age of 43 years (range 36-59), only two patients attained a short-lived response; one patient is alive with active disease at 12 months, five died at 4-14 months. We arrived at the following conclusions: (a) the t(2;3) is a recurrent translocation having an approximate 0.5% incidence in adult AML; (b) breakpoints involve the 5 0 region of EVI1 at 3q26, and the BCL11A, the THADA gene or other regions at 2p16.1-21; (c) cryptic deletions distal to the 3q26 breakpoint may occur in some cases; (d) the juxtaposition of the 5 0 region of EVI1 with regulatory elements normally located on chromosome 2 brings about EVI1 overexpression; (e) clinical outcome in these cases is severe.
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Introduction
Chromosome defects occurring in acute myeloid leukemia (AML) and myelodysplatic syndrome (MDS) are associated with specific gene rearrangements, leading to differentiation block of hemopoietic progenitors, altered response to survival and proliferation signals, disregulation of stem cell maintenance and DNA repair. 1, 2 Cytogenetic features in AML have clinical importance, in that they identify specific disease subsets with distinct prognosis. 3, 4 The involvement of the 3q26 chromosome band was described in myeloid neoplasia, 5 including 1-3% of de novo AML and rare cases of MDS evolving into leukemia. 6, 7 The 3q21q26 syndrome consists of AML or high-risk MDS presenting normal or elevated platelet counts with frequent dismegakaryocytopoiesis and one of two balanced aberrations, namely inv(3)(q21q26) or t(3;3)(q21;q26). 6 These chromosome changes were shown to involve a small region close to the ribophorin gene at 3q21 and sequences located 3 0 of the EVI1 gene at 3q26 in the inv(3) or 5 0 to it in the t(3;3). 8, 9 In both groups EVI1 overexpression is consistently present, 10 along with alteration of the ratio between MDS1/EVI1 and EVI1 transcripts [10] [11] [12] [13] possibly accounting for the unfavorable outcome, which is usually associated with this abnormality. Other rare balanced rearrangements involving the 3q26 band were associated with the overexpression of a chimeric or a wt EVI1 in myeloid neoplasia: in the t(3;21)(q26;q22) and in the t(3;12)(q26;p13) 8, 14 EVI fuses with AML1 and ETV6, respectively, while in the t(3;7)(q26;q21) no chimeric EVI1 transcript was detected. 15 Recently, 21 cases with various myeloid malignancies were described with a translocation t(2;3) involving different breakpoints at 3q26-27 and 2p15-23. 16 We found a balanced translocation, t(2;3)(p15-22;q26-27), in the karyotype of six patients with AML, five of whom were drawn from an unselected series of approximately 1000 patients enrolled in the Italian GIMEMA trials since 1999.
The results of molecular cytogenetic and hematologic studies in these six patients are described in this report.
Patients and methods

Cytogenetic and molecular genetic studies
Centralized cytogenetic analysis according to standard methods was performed since 1999 in every patient enrolled in the Italian GIMEMA trial. One patient included in the present report was diagnosed and treated at the Hematology Institute in Salamanca (Spain). At least 20 mitotic figures were karyotyped in all cases. Karyotype was reviewed in those patients with a translocation t(2;3) and the presence of cryptic deletions at 5q31, 7q22, 12p13, 13q14, and 20q11 was investigated by interphase fluorescence in situ hybridization (FISH), as described previously. 17 All the patients were routinely screened by RT-PCR and Southern blot for the following molecular aberrations: MLL breaks by Southern blotting or by FISH using commercial probes, BCR/ABL, PML/RARA, AML1/ETO, and CBFb/MYH11 by RT-PCR. Starting on 2001, all the patients were also screened for the presence of FLT3 ITD and for the FLT3 D835 mutation. 18 In all cases standardized methods were used for the amplification of major fusion genes associated to AML, as described previously. 19 Characterization of the 2p and 3q26 breakpoints FISH analysis was performed on bone marrow cells of patients at diagnosis. Chromosome preparations were hybridized in situ with probes labeled by nick translation. 20 Briefly, 500 ng of labeled probe was used for FISH experiments; hybridization was performed at 371C in 2 Â SSC, 50% (v/v) formamide, 10% (w/v) dextran sulfate, 5 mg COT1 DNA (Roche, Indianapolis, IN, USA), and 3 mg sonicated salmon sperm DNA, in a volume of 10 ml. Posthybridization washing was at 421C in 2 Â SSC-50% formamide ( Â 3) followed by three washes in 0.1 Â SSC at 601C. Biotin-labeled (Invitrogen, Carlsbad, NM, USA) DNA was detected with DEAC-conjugated streptavidin (blue, Molecular Probe, Eugene, OR, USA). In cohybridization experiments, other probes were directly labeled with Cy3 (red, New England Nuclear, NJ, USA), FluorX (green, Amersham, Buckinghamshire, UK), and Cy5 (IR, New England Nuclear, NJ, USA). Chromosomes were identified by 4 0 -6-diamidino-2-phenylindole (DAPI) stain. Digital images were obtained using a Leica DMRXA epifluorescence microscope equipped with a cooled CCD camera (Princeton Instruments). Cy3, FluorX, Cy5, DEAC, and DAPI fluorescence signals, detected using specific filters, were recorded separately as gray scale images. Pseudocoloring and merging of images were performed using the Adobe Photoshop software. BAC/PAC clones belonging to the Roswell Park Cancer Institute libraries (P de Jong, http://www.chori.org/bacpac/) were selected according to the UCSC genome browser (http:// www.genome.ucsc.edu). Clones FISH mapping was performed on normal controls to confirm their expected chromosomal localization. UCSC database (http://www.genome.ucsc.edu) was also queried for known and predicted genes searching next to breakpoint regions.
A set of BAC/PAC clones specific for EVI1 and MDS1 genes ( Figure 1b and Table 1 ) was employed in FISH experiments to verify their involvement in t(2;3) rearrangements. The probes used to define breakpoints on chromosome 2p are reported in Table 1 and Figure 1 .
For a more precise characterization of the breakpoints, specific long PCR probes for FISH analysis were obtained by using TaKaRa LA Taqt (http://www.takara-bio.co.jp). For chromosome 2p BAC clones RP11-440P5 and RP11-606L8 were employed as template for long PCR in cases # 4 and 5. The list of used primers (both for chromosomes 2 and 3) are available online as Supplementary material. Amplification products obtained by using these primers ranged from about 9 to 14 kb. DNA fragments obtained by using BCL11A1F/BCL11A1R, BCL11A2F/BCL11A2R, BCL11A3F/BCL11A3R, and BCL11A4F/ BCL11A4R, BCL11A5F/BCL11A5R were pooled and named PCR PROBE 2A and PCR probe 2B, respectively (see the Figure 1a ).
For chromosome 3q, BAC clones RP11-82C9 and RP11-250A4 were used as template in long PCR experiments in cases # 5 and 6. Table 1 Probes used for the characterization of the 2p and 3q breakpoints Chromosome 2p21-16
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Hybridization results of each probe to the der(2), der(3) or both derivative chromosomes (split signal) are reported for each patient with the t(2;3). BAC clones employed in FISH experiments to define chromosome 2p breakpoints are listed according to their position on chromosome 2p from the telomere to the centromere. Clones used to define the 3q26 brekpoints are listed starting from the more centromeric one. PCR probes were used in patients 1, 4, 5, 6 (see text for details). Translocation in acute myeloid leukemia M Trubia et al DNA fragments obtained by using EVI1-1F/1R, EVI1-2F/2R, and EVI1-3F/3R, EVI1-4F/4R were pooled and named PCR PROBE 3A and PCR probe 3B, respectively (see the Figure 1b ). The size of amplification fragments ranged from about 10 to 12 kb.
Bioinformatic tools
CpG islands and promoter regions were predicted by using several programs in the UCSC database. Briefly, Geneid and Genscan programs were used to search for predicted genes; First Exon Finder 21 (FirstEF) was used to detect promoter regions; Translocation in acute myeloid leukemia M Trubia et al CpG Island searching program was used to search the sequence one base at a time, scoring each dinucleotide and identifying maximally scoring segments. The cluster number is displayed in parentheses for each item such as promoter and/or CpG islands.
RACE PCR
In those cases with adequate material available (patients # 1-4), total mRNA was extracted from GTC lysed cells and retrotranscribed according to the instructions provided by the 'SMART RACE cDNA amplification kit' (BD Biosciences Clontech, Palo Alto, CA, USA). The primers used are available as Supplementary material. PCR conditions were as suggested in the protocol.
EVI1 expression
Total mRNA was extracted from GTC lysed cells and retrotranscribed into cDNA with Superscript II Rnase H-kit (invitrogen). Part of the resulting cDNA, corresponding to 10 ng of the starting RNA, was used for quantitative PCR amplification. qPCR was carried out in an ABI-PRISM 7700 Sequence Detector (Perkin-Elmer) with SYBR-GREEN (Applied Biosystem). Cycling conditions were as follows: 501C 2 0 (one cycle) and 951C 10 00 , 601C 15 00 (40 cycles). cDNA from different samples was normalized for GAPDH expression. Primers used are available as Supplementary material.
Hematologic studies
Salient hematologic, immunophenotypic, and clinical data were obtained by review of clinical records. Morphology of bone marrow smears was studied and patients were classified according to the FAB criteria 22 and the WHO criteria. 23 
Results
Cytogenetic data and molecular genetic findings
From a cohort of five approximately 1000 patients with AML enrolled in the GIMEMA trials, five patients harbored the t(2;3) as the primary alteration (Supplementary Figure 1a) . Another case with t(2;3) from a separate trial was also studied. Molecular cytogenetic data are presented in Tables 1 and 2 . G-banding analysis identified a common breakpoint cluster region in the 3q26-27 chromosome band. The breakpoints on 2p were assigned to a cytogenetically small region centered on the 2p16 G-band.
FISH mapping of the breakpoints
The outcome of FISH studies is detailed in Table 2 and Figure 1 (see also Figure 1 in Supplementary material).
Chromosome 2p. Scanning of the whole cytogenetic band by FISH analysis showed that the breakpoints clustered in three regions spanning approximately 17 Mbp around the 2p16 band. In cases # 1, 4, and 5 chromosome 2 breakpoint was mapped inside the BAC RP11-606L8, which encompasses the BCL11A (B-cell CLL/lymphoma 11A) gene. 24 To precisely define breakpoints location, FISH experiments with long-PCR amplification products were performed. In case # 4, the probe 2.6 revealed a split signal, showing that the break occurred between BCL11A exons 1 and 2 ( Figure 1a) . In case # 5, FISH cohybridization with PCR probe 2A and 2B revealed signals on der(2) chromosome (data not shown). These experiments confirmed that the breakpoint mapped in the distal part of BCL11A gene. In case # 2 the break was mapped between RP11-90D1 (2p16.1) and RP11-179A20 (2p16.1). In case # 6, FISH analysis with the clone RP11-1069E24 revealed a split signal data (not shown) showing that the breakpoint occurred in 2p21. THADA (thyroid adenoma associated) (Rippe et al., 2003) gene resulted to be disrupted as it completely encompasses the BAC RP11-1069E24. In case # 3 the breakpoint was contained by RP11-339H12, in a position distal THADA gene.
The orientation of the genes altered in chromosome 2 was not compatible with the formation of a chimeric PRDM3 protein.
Chromosome 3q26. FISH experiments revealed that in cases # 1-4 breakpoints occurred inside the MDS1 gene, as shown in Table 1 and Figure 1 .
Interestingly, the use of clones RP11-115B16 and RP11-641D5 in case # 2 revealed the occurrence of chromosome 3 sequence deletion; in fact, the first clone gave a faint signal on der(2), whereas the second hybridized only on normal chromosome 3. Further experiment with the BAC RP11-828P13 (telomeric to RP11-641D5) showed a faint signal on der(2) consenting to estimate that the size of microdeletion was about 170 kb.
In cases # 5 and 6, FISH revealed a breakpoint localization more centromeric compared to that observed in cases # 1 and 2 ( Figure 1b and for case # 6 Supplementary Figure 1b) . To better Figure 1c) . These data demonstrated that chromosome 3 breakpoint was located 5 0 to EVI1 gene, inside MDS1 intron 2. In case # 5, it was not possible to understand the FISH pattern of long-PCR amplification products due to poor sample quality. We cannot therefore exclude that breakpoint position is the same in case # 5 and 6.
Bioinfomatic analysis of breakpoint regions
In cases # 1 and 4, in proximity of BCL11A break, a CpG island and a promoter were predicted by using specific UCSC tracks. Probability score for the promoter prediction was high (0.999). As a consequence of the t(2;3) rearrangement, these regulatory elements were transferred at the 5 0 of EVI1 gene in case # 4, whereas it was not possible to establish if these sequences were juxtaposed to EVI1 gene in case # 1.
In case # 2, by querying UCSC database a promoter(389 þ ) with a high score (1) was found to be located in a region telomeric to the breakpoint. Also in this case the predicted promoter was translocated on der(3) chromosome.
In case # 6 and 3, according to UCSC, a predicted promoter(299 þ ) and a CpG island mapped at the 3 0 of THADA gene; therefore these regulatory sequences were transferred telomerically to EVI1 gene.
RACE PCR studies
As in t(2;3) the breakpoints on chr.2 spread in a wide region and three genes could potentially be involved, we looked for both the existence of fusion transcripts and the expression pattern of PRDM3 isoforms. 14, 25 We performed 5 0 RACE experiments on cases # 1-4, the cases for which RNA was available. Primers were drawn from MDS exon 2 in case # 3 and from EVI exon 4 for all the other cases. While in cases # 1, 2 and 4 only sPRDM3-related transcripts were identified, in case # 3 several chimeric clones, containing sequences from chr. 2 fused with MDS exon 2, were identified. BLAST analysis of the 125 bp sequence fused with MDS1 univocally identified a region 5 kbp distal of ZFP36L2. As confirmation of our data, this sequence matched the genomic clone, BAC RP11-339h12, shown above to be splitted in FISH experiments (see Figure 1c for details).
Despite several 5 0 RACE attempts and RT-PCR experiments, we have not been able to identify longer sequences from chromosome 2p in the chimeric transcripts. Furthermore, because of the opposite orientation of both ZFP36L2 and THADA genes, if compared with PRDM3 locus, it is unlikely that their transcripts could be somehow involved in the fusion.
The fusion transcripts identified were representative of two splicing variants at the donor site of the chromosome 2 exon, while the acceptor site of MDS ex2 was constant. The two donor sites are 97 bp apart and they give rise to two fragments differing for 97 bp. The shorter isoform contains an in-frame start codon supported by a consensus Kozak (ctgATGg) that could initiate (Figure 1c , dashed arrow) a protein pretty much identical with long PRDM3. However, Western blot analysis with antibody specific for MDS/EVI (Abgent, San Diego, CA, USA) failed to identify this protein in the patient examined (data not shown).
q-PCR
PRDM3 locus transcription was assayed by QPCR, normalized for GAPDH, and compared to normal BM samples. Two sets of primers were drawn from exonic sequences specific for only MDS1/EVI1 or for both isoforms. EVI1 overexpression was detected in all assessable patients. Overxpression of the MDS-EVI1 transcript was not detected, with the exception of patient 3, who showed a 60-fold overxpression of MDS-EVI1 transcript as compared with normal controls (Table 2 ).
Hematologic and clinical data
These data are summarized in Table 3 . All patients had de novo AML, with a 2-month MDS phase preceding the onset of AML in one patient (no. 3). As shown in Table 3 , dysplasia affecting at least two myeloid cell lineages, including megakaryocytes, was present in 3/9 cases, which fullfilled the criteria for the diagnosis of AML with multilineage dysplasia (group 2 according to the WHO classification). Two patients had AML-M4 and AML-M2 according to the FAB classification; AML-M1 and AML-M5 were diagnosed in one case each. The patients had no elevated platelet count, while a wide variation in the white blood cell Table 3 Hematologic features Translocation in acute myeloid leukemia M Trubia et al count was observed. Splenomegaly was present in two patients, with concurrent adenopathy in one; no organ involvement occurred at diagnosis in the remaining patients. All patients showed CD34 positivity as well as CD13 and/or CD33 positivity, four out of five cases were CD117 þ ; uncoordinated expression of lymphoid markers was detected in one case.
The patients were treated by the DCE regimen (daunorubicin 45 mg/sqm Â 3 days; cytarabine for 10 days; etoposide for 5 days). One patient attained complete remission (CR), followed by relapse after 6 months; one patient attained a short-lasting CR after a prolonged thrombocytopenic phase, whereas three patients showed resistant disease. A partial, short-lasting response was observed in one patient treated by the D3A7 regimen (daunorubicin for 3 days plus cytarabine for 7 days). Salvage treatment with various regimens, including FLA(N)G (fludarabine for 3 days, high-dose cytarabine, mitoxantrone for 1 day, G-CSF), the anti-CD33 monoclonal antibody (Mylotarg), and allogeneic BMT from HLA-identical sibling donor, failed to induce CR in four patients. Chemoresistance was overcome by transplantation by HLA-identical unrelated donor BMT or by haploidentical BMT in two patients, who died due to infectious complications. One patient is alive with active disease at 12 months, five patients died after 4-14 months.
Discussion
The incidence of the t(2;3)(p15-21;q26-27) was around 0.5% in the GIMEMA database. This anomaly was primary in nature with additional defects of the 'myeloid' type occurring in 3/6 cases.
A similar 0.3% incidence for this translocation was found in the context of large AML series. 26 In two patients with AML with a t(2;3) analyzed in a recent review, 16 the breakpoints could be localized 5 0 to EVI1. Other breakpoint clusters in 3q26 rearrangement were previously identified in a position 3 0 to EVI1 in the inv(3)(q21q26), whereas a fusion between ETV6 or AML1 and MDS1 was documented in the t(3;12)(q26;p13) and (3;21)(q26;q21), respectively. 8 In our study the translocation breakpoints were assigned to bands 3q26-27 and 2p15-21. FISH studies showed a relatively homogeneous breakpoint at band 3q26, in a position 5 0 to EVI1, suggesting that the observed heterogeneity in 3q26 breakpoints reflected inadequate G-banding resolution. The precise location of the breakpoint was identified in five patients, in whom the break occurred within intron 2 of the MDS1 gene (# 1, 2, 4, 6) and in intron 1 (# 3); in one patient (# 5) a region 5 0 of EVI1, spanning from intron 2 to EVI1 exon 1, was involved. Thus, the breakpoint location in our patients functionally recalls the pattern observed in the t(3;3)(q21;q26).
Interestingly, a microdeletion of approximately 170 kb inside MDS1 intron 1 and distal to the 3q26 break was found in one case in this study (# 2), confirming that DNA loss surrounding the translocation breakpoints is a frequent finding in AML. 27 FISH mapping of the breakpoints on chromosome 2p documented that in three patients (# 1, 4, 5) the breaks occurred within a BAC clone encompassing the BCL11A gene at 2p16.1. The break occurred 5 0 and 3 0 of intron 2 in cases # 4 and 5, respectively, while in case # 1 the break was located in a region encompassing exon 1 and part of intron 2.
In the remaining three cases, the breakpoints were evenly distributed in two regions. In case # 2 no gene was apparently involved in the rearrangement, while in the other two cases (# 3 and 6) the breaks clustered into and 3 0 to the thyroid adenoma associated gene (THADA), respectively. However, it is noteworthy that in all the cases the chromosome 2 breakpoints were not predictive of a fusion gene with EVI1 because of the opposite orientation of BCL11A and THADA.
In one of the five patients analyzed by RACE (# 3), we found a fusion transcript. The chromosome 2-derived sequence was located 5 kbp distal of ZFP36L2 gene, thus supporting the hypothesis that the rearrangements uncovered a cryptic promoter in chromosome 2. The absence of chimeric transcripts in the other cases, the similarity with t(3;3) in the breakpoint localization on chromosome 3, and the presence of putative promoter regions support the idea that the main event in the 3q26 leukemogenesis is mediated by the altered expression of transcripts form the PRDM3 locus.
EVI1 overexpression of 21-58-fold was detected in our cases, with normal or absent MDS1/EVI1 expression in four of five cases tested. Even though in case # 3 both transcripts were detected, no MDS/EVI protein was seen by Western blot analysis. This suggests that, while a promoter activity was efficiently provided by chromosome 2, at least in case # 3, the only protein produced derived from the EVI1 transcript. In the remaining cases the breakpoint lay upstream EVI1 first exon and the only transcript detectable derived from EVI1 natural promoter. In all the cases analyzed, the alteration of the PRDM3 locus resulted in an increased transcription of EVI1 and in the consequent decrease of the MDS-EVI1/EVI1 protein ratio. While these two proteins are expressed in hemopoietic stem cells, the level of EVI1 falls during differentiation. 11 An aberrant expression of EVI1 leads to BM hyperproliferation 28 and induces a myelodysplastic syndrome in mice transplanted with EVIexpressing cells.
Our patients presented a relatively homogeneous hematologic picture. Unlike other patients with 3q26 rearrangements, elevated platelet counts were not observed and hyperleukocytosis was not detected in 5/6 cases. Resistance to conventional treatment suggests that alternative protocols should be offered as first-line treatment to these patients.
In conclusion, we have characterized six AML patients harboring the t(2;3) translocation, showing that (a) the t(2;3) is a nonrandom chromosome aberration occurring in approximately 0.5% of de novo AML; (b) it involves the MDS1 gene and the 5 0 region of EVI1 at 3q26 and distinct regions on chromosome 2p16-21, disrupting the THADA gene and the BCL11A gene in some cases; (c) cryptic deletions distal to the 3q26 breakpoint may occur in some cases; (d) the t(2;3) brings about the juxtaposition at 3q26 of the PRDM3 locus with regulatory elements normally located in proximity of the 2p breakpoints, with consequent EVI1 overexpression and fusion transcript in one case; (e) the t(2;3) is associated with a disease displaying multilineage dysplasia without elevated platelet count, an immature myeloid phenotype, and dismal outcome due to primary chemoresistance.
